NASDAQ$TECH
Bio-Techne Corp · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Bio-Techne's Q3 2020 performance reflected resilience amidst the COVID-19 pandemic, with organic revenue growth and adjusted EPS increase.
Bio-Techne reported a 5% increase in net sales to $194.7 million for Q3 2020, with organic growth of 6%. GAAP EPS decreased to $0.92, while adjusted EPS increased to $1.39. The company highlighted its role in combating COVID-19 and maintained a strong financial position.
- Organic revenue increased by 6% to $194.7 million.
- GAAP EPS was $0.92, while adjusted EPS reached $1.39.
- Adjusted Operating Margin increased to 36.4%.
- The company is actively involved in developing COVID-19 solutions.
Headline financials
Revenue & EPS history
Bio-Techne · Revenue · Quarterly
$195M
Revenue by segment
Bio-Techne · $146M total across 1 segment · Q3 2020
- Protein Sciences$146M+5.5%100.0%
Forward guidance
The company anticipates customer site shutdowns to negatively impact sales while they remain in effect, but also expects long-term positive sales growth due to increased funding in life-science research in response to the pandemic. They also expect short and long term impacts of COVID-19 on adjusted EPS to be similar to that of sales growth.
Tailwinds
- Positive long-term outlook for future sales growth from expected future funding increases within life-science research in response to the current pandemic
- Company has responded to COVID-19 by developing resources for SARS-CoV-2 detection, cytokine monitoring, and drug discovery
- The Company continues to pursue available opportunities to partner in the fight against COVID-19
- Company remains in a strong financial position with sufficient available cash
- Company remains fully operational
Headwinds
- COVID-19 negatively impacted sales growth during the third quarter of fiscal year 2020 due to numerous customer site shutdowns
- Customer site shutdowns will continue to have a negative impact on sales while they remain in effect
- Company is currently unable to forecast the impact given uncertainty over the duration of the COVID-19 pandemic
- Adjusted EPS was negatively impacted by COVID-19 by an estimated $0.07-$0.09 in the third quarter of fiscal 2020
- The COVID-19 impact on adjusted EPS was primarily due to the sales impacts
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+0.8%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+1.8%
Avg return
30 days after
58%
39 / 67 earnings
Positive
+19.6%
Q3 2024
Best reaction
-9.0%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.0% | -18.3% | -8.1% | |
| Q2 2026 | +4.8% | +1.3% | -16.6% | |
| Q1 2026 | -1.9% | -6.0% | +0.9% | |
| Q3 2025 | +2.2% | +13.0% | +2.0% | |
| Q2 2025 | +3.7% | -3.6% | -11.3% | |
| Q1 2025 | +4.3% | +7.3% | +6.5% | |
| Q4 2024 | -6.4% | -8.5% | -8.8% | |
| Q3 2024 | +19.6% | +20.3% | +22.1% | |
| Q2 2024 | -6.2% | -4.2% | +5.8% | |
| Q1 2024 | -6.7% | +3.7% | +11.1% | |
| Q4 2023 | +2.1% | +3.8% | -9.0% | |
| Q3 2023 | +4.8% | +2.6% | +3.5% | |
| Q2 2023 | -2.6% | -3.5% | -3.7% | |
| Q1 2023 | +0.6% | +2.5% | +16.7% | |
| Q4 2022 | -2.3% | -7.8% | -15.8% | |
| Q3 2022 | +0.7% | -9.5% | -5.3% | |
| Q2 2022 | +11.0% | +8.9% | +11.5% | |
| Q1 2022 | -3.9% | -5.3% | -11.0% | |
| Q4 2021 | -1.0% | -4.7% | +5.4% | |
| Q3 2021 | +1.5% | -0.3% | +1.8% | |
| Q2 2021 | +8.3% | +11.9% | +2.3% | |
| Q1 2021 | +13.2% | +12.4% | +14.8% | |
| Q4 2020 | -3.9% | -4.7% | -10.1% | |
| Q3 2020 | +7.7% | +16.5% | +25.4% | |
| Q2 2020 | -0.3% | -3.0% | -6.4% | |
| Q1 2020 | +0.0% | +0.6% | +6.1% | |
| Q4 2019 | -4.6% | -3.7% | -4.8% | |
| Q3 2019 | +3.0% | +4.8% | -0.7% | |
| Q2 2019 | +5.3% | +3.3% | +7.3% | |
| Q1 2019 | -5.5% | -4.1% | -8.5% | |
| Q4 2018 | +5.0% | +5.8% | +12.8% | |
| Q3 2018 | -2.8% | -1.4% | +0.1% | |
| Q2 2018 | +3.0% | +0.8% | +8.6% | |
| Q1 2018 | +3.8% | +4.6% | +9.0% | |
| Q4 2017 | -1.5% | +1.1% | +3.8% | |
| Q3 2017 | +2.0% | +3.0% | +5.3% | |
| Q2 2017 | -1.0% | +2.3% | +6.2% | |
| Q1 2017 | +0.3% | -1.6% | +4.3% | |
| Q4 2016 | -3.4% | -2.8% | -2.6% | |
| Q3 2016 | +7.1% | — | — | |
| Q2 2016 | +4.9% | — | — | |
| Q1 2016 | -9.0% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | +1.6% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | -2.8% | — | — | |
| Q4 2014 | +0.2% | — | — | |
| Q3 2014 | +8.1% | — | — | |
| Q2 2014 | -4.4% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | +4.1% | — | — | |
| Q3 2013 | +0.4% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | -4.3% | — | — | |
| Q4 2012 | -3.8% | — | — | |
| Q3 2012 | +0.5% | — | — | |
| Q2 2012 | +2.2% | — | — | |
| Q1 2012 | -5.3% | — | — | |
| Q4 2009 | +1.4% | — | — | |
| Q4 2011 | +1.4% | — | — | |
| Q3 2011 | +0.5% | — | — | |
| Q3 2010 | +0.5% | — | — | |
| Q2 2011 | -0.8% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q4 2010 | +0.6% | — | — | |
| Q1 2010 | +0.6% | — | — | |
| Q2 2010 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro